Targeted News Service logo

-- Preview Email Newsletter
Journals Media Newsletter for 2026-10-10 ( 8 items )  
Alumni awards 2026 (10)
COLUMBIA, South Carolina, Oct. 9 -- The University of South Carolina posted the following news: * * * Alumni awards 2026 * Camera pans from an overhead view of campus to a view of a statue through a crowd to a shot of a building to a view of a fountain to a receding view of the USC smokestack. Each year, the University of South Carolina celebrates exemplary alumni and friends with six key awards. Bestowed by the Alumni Association, the awards reflect the values that define the Gamecock community: service, integrity, character and leadershi more PR

Better Markets Analysis: 'Prediction Markets,' Gambling, the CFTC and Regulation - Facts, Fiction and The Law (10)
WASHINGTON, Oct. 10 (TNSLrpt) -- Better Markets, an organization that says it promotes pro-market, pro-business and pro-growth policies to help build a better financial system, issued the following analysis: * * * October 9, 2026 "Prediction Markets," Gambling, the CFTC & Regulation: Facts, Fiction & The Law Introduction Since 2022, Better Markets has been deeply engaged in the debates over so-called "prediction markets," first at the Commodities Futures Trading Commission (CFTC) and then in the courts, media, at other agencies, and now vi more PR

Center for European Policy Analysis Issues Commentary: Putin and Xi United by a Love of Corruption (10)
WASHINGTON, Oct. 10 -- The Center for European Policy Analysis issued the following commentary: * * * Putin and Xi United by a Love of Corruption Failure to address corruption has weakened democracies and enabled organized crime, but Russia and China use graft an instrument of state control. By Walter Clemens October 9, 2026 Countries in Eastern Europe and Central Asia are among the world's worst for corruption, with widespread impunity driven by the vested interests that dominate many of their governments. Western European nations fill  more PR

Jamestown Foundation Issues Commentary: Yemen Becomes the Islamic State's Media Sanctuary (10)
WASHINGTON, Oct. 10 -- The Jamestown Foundation issued the following commentary on Oct. 9, 2026, in the foundation's Terrorism Monitor: * * * Yemen Becomes the Islamic State's Media Sanctuary Sara Harmouch | Mohammad Bin Faisal Executive Summary * The September 1 killing of Islamic State (IS) spokesman Abu Hudhayfah al-Ansari in Say'un exposed Yemen's larger role in the organization's media system. * Yemeni sources identify al-Ansari as IS-Yemen's governor, making him more than the organization's public voice. * Yemen had become a sanc more PR

New York Medical College: Advancing Knowledge, One Publication at a Time (10)
VALHALLA, New York, Oct. 10 -- New York Medical College issued the following news: * * * Advancing Knowledge, One Publication at a Time NYMC Honors 378 Faculty Authors Whose 797 Publications Advanced Medicine, Science, and Education Throughout 2025 October 09, 2026 The breadth and impact of NYMC faculty scholarship were on full display at the 33rd Annual Faculty Author Celebration and Awards on October 8. Organized by the Phillip Capozzi, M.D., Library in collaboration with the Office of the Chancellor and the Office of the Vice President  more PR

NYU Law Birbaum Women's Leadership Center Executive Director Weiss-Wolf Testifies Before Senate Special Committee on Aging (10)
WASHINGTON, Oct. 9 -- The Senate Special Committee on Aging released the following testimony by Jennifer Weiss-Wolf, executive director of the New York University Law Birbaum Women's Leadership Center, from a Sept. 16, 2026, hearing entitled "Half the Country, Zero Hearings: Meeting the Moment to End the Menopause Care Gap in America": * * * Thank you Chair Scott, Ranking Member Gillibrand, and Members of the Committee for convening this historic hearing. My name is Jennifer Weiss-Wolf and I am an attorney, advocate, and author whose primary  more PR

U.S. Food & Drug Administration Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine, Oxaliplatin for Adjuvant Treatment of a Certain Type of Stage III Colon Cancer (10)
SOUTH SAN FRANCISCO, California, Oct. 10 (TNSrep) -- Genentech, a member of the Roche Group, issued the following news release: * * * FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for The Adjuvant Treatment of a Certain Type of Stage III Colon Cancer * FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alon more PR

U.S. Food & Drug Administration Approves Roche's Tecentriq in Combination With a Fluoropyrimidine, Oxaliplatin for Adjuvant Treatment of a Certain Type of Stage III Colon Cancer (10)
BASEL, Switzerland, Oct. 10 (TNSrep) -- Roche, a biotech company, issued the following news release: * * * FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer * FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone/1 * First approved adjuvant  more PR